{
  "id": 7582296,
  "title": "Beyond the breakthrough for RAS-driven cancers",
  "url": "https://urgent.news/2026/09/15/beyond-the-breakthrough-for-ras-driven-cancers",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04610-4"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04610-4 Two early clinical studies of selective KRASG12D inhibitors show encouraging activity in advanced cancers with G12D mutations, signaling a transformative change in the treatment landscape for RAS-driven cancers with potential applications across tumor types and stages of disease.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}